RxDoctor Payments Data

Benjamin Kurz, MD

Gastroenterology · Baton Rouge, LANPI 1710229596

Payments from drug & device makers

$6,379in general payments, 2019–2025

Across 383 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$739
  • Takeda Pharmaceuticals U.S.A., Inc.$618
  • Bristol Myers Squibb$468
  • Johnson & Johnson$368
  • Pfizer$268
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$6,23898%
  • Education$1412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,379 in reported general payments places this provider in the 65th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$167,269
Medicare patients
191
Services billed
6,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide28$27,528
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C35$4,730
ClenpiqSod Picosulf/Mag Ox/Citric Ac28$4,605
Budesonide EcBudesonide17$3,016
Lubiprostone18$2,970
Pantoprazole Sodium232$2,837
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates40$2,763
Colestipol Hcl31$2,707
Omeprazole45$1,233
Esomeprazole Magnesium22$905
Dicyclomine Hcl62$767
Sucralfate17$341
Ondansetron OdtOndansetron39$322
Metronidazole16$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,790$27,52828 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$739$4,73035 claims
Ferring Pharmaceuticals Inc.Clenpiq$88$4,60528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →